Learn about all the new features in ADMET Predictor 7.0 and how they can help you.
Simulations Plus Sets Date for 1st Quarter 2014 Earnings Release and Conference Call
Conference Call to be on Thursday, January 9, at 4:15 PM ET
Simulations Plus Reports First-Quarter FY2014 Financial Results
Net sales increase 15.3% to first quarter record $2.641 million; Earnings up 16.7%
Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium
Pyrvinium pamoate (PP) is a potent noncompetitive inhibitor of the androgen receptor (AR). Using a novel method of target identification, we demonstrate that AR is a...
Evaluation and Optimisation of Current Milrinone Prescribing for the Treatment and Prevention of Low Cardiac Output Syndrome in Paediatric Patients After Open Heart Surgery Using a Physiology-Based Pharmacokinetic Drug-Disease Model
Milrinone is the drug of choice for the treatment and prevention of low cardiac output syndrome (LCOS) in paediatric patients after open heart surgery across Europe.
Population Pharmacokinetic Evaluation of Eslicarbazepine Acetate for Adjunctive Therapy in Refractory Partial Onset Seizures
Eslicarbazepine acetate (ESL), a once-daily antiepileptic drug (AED), is converted to eslicarbazepine, the primary active metabolite of ESL, after oral administration. The population pharmacokinetics (PK)…
Design, Synthesis, and in vitro Testing of Novel COX-2/COX-1 Inhibitors
To design,synthesize,and test new lead molecules that inhibit both COX-1 and COX-2 forms of the cyclooxygenase (COX) enzyme, with higher affinity for COX-2 than for COX-1.
Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury
The drug development industry faces multiple challenges in the realization of safe effective drugs.
Faruqi & Faruqi, LLP Launches An Investigation Against Simulations Plus, Inc. (SLP) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Simulations Plus, Inc.
Simulations Plus Reports Preliminary Revenues for First Fiscal Quarter FY2014
Revenues Increase 14.9% for New Record 1st Quarter
Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data
Fourteen drugs targeting protein kinases have been approved by the United States Food and Drug Administration (FDA) between the years 2000 and 2011.
3D QSAR and pharmacophore study of curcuminoids and curcumin analogs: Interaction with thioredoxin reductase
Curcumin is the yellow pigment of Curcuma longa that irreversibly inhibits the activity of thioredoxin reductase (TrxR) and forms adduct.
Simulations Plus Announces Change in Chief Financial Officer
John R. Kneisel, CPA, to Replace Momoko Beran, Retiring after More Than 20 Years of Service
Small-molecule inhibitors of the androgen receptor
The present invention provides tetrahydropyrvinium (THP), derivatives thereof, benzoxazole compounds, and derivatives thereof.
Simulations Plus to Present at the LD MICRO Sixth Annual Conference
Leading Provider of Simulation and Modeling Software for Pharmaceutical Discovery and Development to Present on December 3, 2013
Simulations Plus Reports FY2013 and Fourth Quarter FY2013 Financial Results
Fiscal Year Pharmaceutical Software and Services Up 6.6%
Preoperative androgen deprivation therapy for localized prostate cancer: delayed biochemical recurrence in high-risk disease
Background: The role of preoperative ADT for localized prostate cancer is controversial; prospective assessments have yielded varying results. We sought to define a subset...
Largest Chinese CRO, WuXi PharmaTech, Purchases Multiyear ADMET Predictor License
Toxicity predictions to be used to supplement in vitro data as a service
Prediction of Valsartan Pharmacokinetics in Pediatric Population using Physiologically Based Pharmacokinetic (PBPK) Model
A method for transporter-based in vitro-in vivo extrapolation (IVIVE) was previously developed and demonstrated by predicting valsartan PK after i.v.administration [1]. The purpose of this study was to…